Amarin posts first profitable quarter in two years as VAZKEPA growth accelerates in Europe

Amarin Corporation plc reported financial results for the third quarter ended September 30, 2026 on October 28, 2026. CFO Peter Fishman said the company reported its first profitable quarter in over two years, reflecting a lower expense base and the absence of charges following completed $70 million cost savings initiatives.¹ The company generated positive free cash flow for the fourth consecutive quarter, with cash exceeding $323 million and no debt on the balance sheet.¹

On the commercial side, in-market demand for VAZKEPA in Europe increased by an estimated 68% in Q3 2026 versus Q3 2025, reflecting increased investment by Recordati S.p.A. under its exclusive license and supply agreement.¹ As of September 30, 2026, VASCEPA/VAZKEPA was commercially available in 22 countries, including 11 in Europe through Recordati, with the Recordati agreement covering 59 countries and patent protection extending through 2039.¹ VAZKEPA launched into the private pay market in Poland in October 2026.¹ In the U.S., Amarin's IPE market share was 47% in Q3 2026 amid generic competition.¹

On the pipeline, the company announced findings on October 25, 2026 from the EPA for Metastasis Trial 2 (EMT2), an investigator-initiated Phase 3 trial sponsored by the University of Leeds and funded by Yorkshire Cancer Research, presented at the ESMO 2026 Congress in Madrid.¹ The research examined VAZKEPA/VASCEPA as an add-on therapy for patients undergoing liver resection for colorectal cancer liver metastases, using VASCEPA at the same dose as in the REDUCE-IT cardiovascular outcomes study.¹

The company said it expects combined in-market demand across its global partner markets to continue growing on a sequential quarterly basis.¹ U.S. volumes are expected to remain broadly stable for the remainder of FY 2026.¹